You can now read 5 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

BU disease lab clears environmental review

Boston University’s bid to study some of the world’s deadliest infectious diseases in a South End laboratory has cleared another regulatory hurdle.

The state secretary for environmental affairs issued a certificate Friday indicating that an environmental impact ­report submitted by BU for the National Emerging Infectious Disease Laboratory is complete enough to comply with state law.

Continue reading below

The review has been a point of contention for years, with opponents arguing that not enough had been done to ­examine the potential impact of bringing dangerous pathogens to the densely populated city neighborhood, particularly if the lab were attacked.

The state Supreme Judicial Court agreed in 2007 that not enough had been done to ­examine such risks, prompting a lengthy federal review that was completed in January when the National Institutes of Health issued a decision saying the facility posed minimal risk.

State Secretary of Energy and Environmental Affairs Richard K. Sullivan Jr. found that the review “adequately and properly complies” with state environmental law.

The project, which is funded by NIH, still needs permits for traffic and sewer use and a review by the Boston Public Health Commission.

But Sullivan’s certification “is really the last significant state step that we have to go through,” said BU spokesman Steve Burgay.

The project is still subject to state and federl lawsuits. Christine M. Griffin, an attorney for residents of the neighborhood, said opponents would reinitiate their legal challenge to the environmental review.

Because the lab is located in a neighborhood designated as one where residents have been disproportionately exposed to environmental hazards, state law requires closer scrutiny. The review approved Friday still falls short, said Jennifer Rushlow, an attorney for the Conservation Law Foundation.

The 192,000-square-foot lab was designed to study the most lethal Level 4 infectious agents such as the Ebola virus.

With the state approval in hand, BU said it would begin performing research in the lab on less dangerous Level 3 germs. Burgay said the lab will immediately seek permission from the city of Boston to move tuberculosis research, now conducted in a facility across the street, to the $200 million lab, which has been mostly ­vacant since its construction was completed about four years ago.

Chelsea Conaboy can be reached at cconaboy@
boston.com
. Follow her on Twitter @cconaboy.
Loading comments...
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com
Already a subscriber?
Your city. Your stories. Your Globe.
Yours FREE for two weeks.
Enjoy free unlimited access to Globe.com for the next two weeks.
Limited time only - No credit card required!
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.
Thanks & Welcome to Globe.com
You now have unlimited access for the next two weeks.
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.